Non-Monograph Drugs Interim Marketing Preservation Urged By CHPA
This article was originally published in The Rose Sheet
Executive Summary
FDA's proposed rule on "material time, material extent" criteria for inclusion of drug conditions in the OTC review would "effectively terminate" the monograph process, CHPA maintains in a March 22 letter to the agency.
You may also be interested in...
Marketing Dosage Units "Difficult" To Determine For Certain OTCs - H&R
Foreign marketing data for classes of OTC drugs without specific dosage instructions should be based on annual sales of the active ingredient rather than the finished product, raw material supplier Haarmann & Reimer states in March 21 comments on FDA's "material time, material extent" proposed rule.
Marketing Dosage Units "Difficult" To Determine For Certain OTCs - H&R
Foreign marketing data for classes of OTC drugs without specific dosage instructions should be based on annual sales of the active ingredient rather than the finished product, raw material supplier Haarmann & Reimer states in March 21 comments on FDA's "material time, material extent" proposed rule.
Pfizer Rid Mousse Pediculicide Approved Under "NDA Deviation"
FDA approved an "NDA Deviation" (21-043) for Pfizer's Maximum Strength Rid Mousse aerosolized foam lice treatment March 7.